Personas / Equipo Humano

Susana Rives Solà

Buscador de publicaciones

Publicaciones

  • Ruiz-Llobet A, Gassiot S, Sarrate E, Zubicaray J, Rives-Solà S, Suleman W and Berrueco R.

    Thrombin Generation Profile Using ST-Genesia after PEG-asparaginase in Pediatric Patients with Acute Lymphoblastic Leukemia.

    THROMBOSIS AND HAEMOSTASIS . 124(10): 973-985.

    [doi:10.1055/a-2316-4547]

  • Pennesi E, Brivio E, Ammerlaan ACJ, Jiang Y, Van der Velden VHJ, Beverloo HB, Sleight B, Locatelli F, Brethon B, Rossig C, Engstler G, Nilsson A, Bruno B, Petit A, Bielorai B, Rizzari C, Rialland F, Rubio-San-Simón A, Sirvent FJB, Diaz-de-Heredia C, Rives-Solà S and Zwaan CM.

    Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22(+) acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial.

    HAEMATOLOGICA . 109(10): 3157-3166. Nº de citas: 4

    [doi:10.3324/haematol.2023.284409]

  • Wu JH, Pennesi E, Bautista F, Garrett M, Fukuhara K, Brivio E, Ammerlaan ACJ, Locatelli F, van der Sluis IM, Rossig C, Chen-Santel C, Bielorai B, Petit A, Starý J, Díaz-de-Heredia C, Rives-Solà S, O'Marcaigh A, Rizzari C, Engstler G, Nysom K, Rubio-San-Simón A, Bruno B, Bertrand Y, Brethon B, Rialland F, Plat G, Dirksen U, Sramkova L, Zwaan CM and Huitema ADR.

    Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059.

    CLINICAL PHARMACOKINETICS . 63(7): 981-997.

    [doi:10.1007/s40262-024-01386-z]

  • Juan-Ribelles A, Bautista F, Cañete A, Rubio-San-Simón A, Alonso-Saladrigues A, Hladun R, Rives-Solà S, Dapena JL, Fernández JM, Lassaletta Á, Cruz-Martínez O, Ramírez-Villar G, Fuster JL, de Heredia CD, García-Ariza M, Quiroga E, Del Mar Andrés M, Verdú-Amorós J, Molinés A, Herrero B, López M, Márquez C, Toboso M, Lendínez F, Sirvent JG, Tallón M, Rodríguez G, Acha T, Moreno L and Fernández-Teijeiro A.

    ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer

    CLINICAL & TRANSLATIONAL ONCOLOGY . 26(9): 2351-2359.

    [doi:10.1007/s12094-024-03445-0]

  • Rossig C, Pearson AD, Vassal G, Scobie N, Bird N, Blanc P, Vormoor HJ, Calkoen FG, Locatelli F, Bufalo FD, Rives-Solà S, Jacoby E, Balduzzi A, Bourquin JP and Baruchel A.

    Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed.

    JOURNAL OF CLINICAL ONCOLOGY . 42(3): 253-257. Nº de citas: 4

    [doi:10.1200/JCO.23.01314]

  • Molinos-Quintana Á, Alonso-Saladrigues A, Herrero B, Caballero-Velázquez T, Galán-Gómez V, Panesso M, Torrebadell-Burriel M, Delgado-Serrano J, Pérez de Soto C, Faura A, González-Martínez B, Castillo-Robleda A, Diaz-de-Heredia C, Pérez-Martínez A, Pérez-Hurtado JM, Rives-Solà S and Pérez-Simón JA.

    Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

    FRONTIERS IN IMMUNOLOGY . 14: 1280580-1280580. Nº de citas: 5

    [doi:10.3389/fimmu.2023.1280580]

  • Rives-Solà S.

    Central nervous system therapy in acute lymphoblastic leukemia: no more, no less.

    HAEMATOLOGICA . 108(12): 3193-3194.

    [doi:10.3324/haematol.2023.283275]

  • Velasco P, Bautista F, Rubio A, Aguilar Y, Rives-Solà S, Dapena JL, Pérez A, Ramirez M, Saiz-Ladera C, Izquierdo E, Escudero A, Camós-Guijosa M, Vega-García N, Ortega M, Hidalgo-Gómez G, Palacio C, Menéndez P, Bueno C, Montero J, Romecín PA, Zazo S, Alvarez F, Parras J, Ortega-Sabater C, Chulián S, Rosa M, Cirillo D, García E, García J, Manzano-Muñoz A, Minguela A and Fuster JL.

    The relapsed acute lymphoblastic leukemia network (ReALLNet): a multidisciplinary project from the spanish society of pediatric hematology and oncology (SEHOP)

    Frontiers in pediatrics . 11: 1269560-1269560.

    [doi:10.3389/fped.2023.1269560]

  • Marina Caballero Bellón, Alonso-Saladrigues A, Bobillo-Perez S, Faura A, Arqués L, Rivera C, Català-Temprano A, Dapena JL, Rives-Solà S and Jordán-García I.

    Risk factors and outcome of Chimeric Antigen Receptor T-Cell patients admitted to Pediatric Intensive Care Unit: CART-PICU study

    FRONTIERS IN IMMUNOLOGY . 14: 1219289-1219289. Nº de citas: 3

    [doi:10.3389/fimmu.2023.1219289]

  • Esperanza-Cebollada E, Gomez-Gonzalez S, Pérez-Jaume S, Vega-García N, Vicente-Garces C, Richarte M, Rives-Solà S, Català-Temprano A, Torrebadell-Burriel M and Camós-Guijosa M.

    A miRNA signature related to stemness identifies high-risk patients in paediatric acute myeloid leukaemia

    BRITISH JOURNAL OF HAEMATOLOGY . 202(1): 96-110. Nº de citas: 5

    [doi:10.1111/bjh.18746]